NASDAQ · JAZZ

Jazz Pharmaceuticals, Inc.

$255.43 +$1.56 (+0.61%) 1D After hours
Charting by TradingView

Key Metrics

$15.95B
Market cap
41.35×
P/E · TTM
$171.06M
Revenue · TTM
$385.64M
Net income
EPS · TTM $6.32
Dividend yield —
Free cash flow —
Beta · 1Y 0.43
EBITDA · TTM —
Gross margin —

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Feb 25
    The stock moved +13.2% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 25

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$15.95B
Enterprise value$19.46B
Shares outstanding62.8M
52-wk range$105.00 – $257.00
Avg volume · 20D706.1K
Net cash −$3.51B
Book value / share$74.30
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About Jazz Pharmaceuticals, Inc.
IPO dateJun 1, 2007
Employees2890

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology.

Wolf Grade COMING SOON

—

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E41.35
P/S93.23
P/FCF—
EV/EBITDA—
EV/Sales113.75
Graham №$102.80

Profitability

Gross —
Operating 229.4%
Net 225.4%
FCF —
ROE / ROIC 8.5% · —

Financial Health

Current ratio2.04
Quick ratio1.85
Debt / equity1.18
Debt / EBITDA —
Net cash −$3.51B
Working capital$2.34B

Cash Flow · TTM

Operating CF —
Capex —
Free cash flow —
Buybacks —
Dividends paid —
Shareholder yield —

Piotroski F-Score

0 / 9
Weak fundamentals · 0 of 9 signals passing

Altman Z-Score

—
Insufficient balance-sheet inputs

Graham Number vs Price

$102.80 vs $255.43
Trades 2.5× above classic defensive value — priced for growth
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings